Celcuity, Inc. (NASDAQ:CELC) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by Brian Himes on Sep 12th, 2026

Shares of Celcuity, Inc. (NASDAQ:CELC – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $154.5455.

Several equities research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Celcuity from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Stifel Nicolaus lowered their target price on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a report on Friday, August 14th. Macquarie Infrastructure set a $160.00 target price on shares of Celcuity in a research report on Thursday, May 28th. Citigroup reiterated a “market outperform” rating on shares of Celcuity in a research note on Monday, August 17th. Finally, Leerink Partners set a $155.00 price target on shares of Celcuity in a research report on Tuesday, June 2nd.

Read Our Latest Research Report on CELC

Institutional Trading of Celcuity

A number of large investors have recently made changes to their positions in CELC. NEA Management Company LLC increased its stake in Celcuity by 64.9% in the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after buying an additional 1,391,300 shares during the period. Avoro Capital Advisors LLC acquired a new stake in shares of Celcuity in the 4th quarter valued at approximately $310,302,000. Soleus Capital Management L.P. grew its holdings in Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares during the period. Vanguard Group Inc. grew its stake in shares of Celcuity by 10.7% during the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after purchasing an additional 220,386 shares during the period. Finally, California State Teachers Retirement System grew its stake in shares of Celcuity by 7,330.1% during the 2nd quarter. California State Teachers Retirement System now owns 1,900,632 shares of the company’s stock worth $198,844,000 after purchasing an additional 1,875,052 shares during the period. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Trading Down 2.4%

Shares of NASDAQ CELC opened at $83.45 on Monday. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The stock has a market capitalization of $4.08 billion, a PE ratio of -19.41 and a beta of 0.19. Celcuity has a twelve month low of $44.42 and a twelve month high of $151.02. The stock has a fifty day simple moving average of $92.98 and a 200-day simple moving average of $106.19.

Celcuity (NASDAQ:CELC – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, equities analysts forecast that Celcuity will post -4.75 earnings per share for the current year.

About Celcuity

(Get Free Report)

Celcuity, Inc is a biotechnology company focused on advancing personalized medicine through functional diagnostics. Its technology is designed to analyze living tumor cells obtained from patient tissue and identify abnormal signaling activity that may influence how a cancer responds to specific therapies.

The company’s primary platform, CELsignia, uses proprietary assays to measure the activity of cellular signaling pathways in a patient’s tumor cells. Celcuity develops these tests for use in oncology drug development, patient selection, and potentially as companion diagnostics to help identify patients who are most likely to benefit from targeted treatments.

Celcuity works with biopharmaceutical companies and research organizations to evaluate drug-response biomarkers and support precision oncology programs.